Metis TechBio in deal for experimental autoimmune drug worth up to $1.6 billion

• Boulevard Bio will pay Metis TechBio $20 million upfront, with up to $1.6 billion in additional milestone payments tied to development, regulatory, and commercial achievements
• MTS-128's development showcases Metis TechBio's capability to integrate artificial intelligence with protein drug design for autoimmune indications
• The deal comes as Beijing tightens oversight of U.S. investment in Chinese firms developing frontier technologies, following recent forced divestitures like Meta's $2 billion-plus Manus AI acquisition

Summary: Metis TechBio Licenses Autoimmune Drug to Boulevard Bio

Deal Overview:

Hong Kong-listed Metis TechBio has granted U.S.-based Boulevard Bio exclusive global rights to develop, manufacture, and commercialize its experimental autoimmune drug MTS-128 in a deal valued up to $1.6 billion.

Financial Terms:

• $20 million upfront payment to Metis TechBio
• Up to $1.6 billion in milestone payments tied to development, regulatory approval, and commercial success
• Total deal value includes all milestone achievements

Key Companies:

• Metis TechBio: Hong Kong-listed drug design technology firm specializing in AI-integrated protein drug design
• Boulevard Bio: U.S.-based biotechnology company acquiring worldwide rights to MTS-128

Product Details:

MTS-128 is an experimental drug targeting autoimmune indications, developed using Metis TechBio's AI-integrated protein drug design platform. Specific disease targets were not disclosed in the announcement.

Market Implications:

The deal represents a significant advancement in U.S.-China technology collaboration amid heightened scrutiny of cross-border deals involving sensitive technologies. Beijing has increased oversight of U.S. investment in Chinese firms developing frontier technologies, exemplified by Meta's unwinding of its $2+ billion acquisition of AI startup Manus earlier this year.

This transaction demonstrates that strategic biotech partnerships can still progress despite geopolitical tensions, particularly when involving innovative AI-driven drug development platforms. The substantial milestone structure suggests confidence in MTS-128's commercial potential while managing risk for Boulevard Bio.

Date: Announced June 30 (per Reuters)